NP137
Sponsors
Netris Pharma, NETRIS Pharma, University Hospital, Grenoble, Centre Leon Berard, Aram Hezel
Conditions
Acute Myeloid Leukemia RefractoryAdvanced Solid TumorsCervix CarcinomaEndometrial CarcinomaHepatocellular CarcinomaMetastatic Solid TumorsPancreatic CancerPancreatic Ductal Adenocarcinoma
Phase 1
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
Active, not recruitingNCT04652076
Start: 2020-12-14End: 2026-07-30Target: 240Updated: 2024-10-08
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
CompletedNCT05546853
Start: 2023-03-28End: 2025-06-16Updated: 2026-02-06
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
SuspendedNCT05546879
Start: 2023-03-15End: 2027-03-15Updated: 2026-02-10
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
TerminatedNCT06150040
Start: 2024-09-11End: 2025-02-18Updated: 2025-02-20
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
Not yet recruitingNCT06203821
Start: 2026-09-01End: 2032-09-30Target: 25Updated: 2026-02-05
Phase 2
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
Active, not recruitingNCT05605496
Start: 2023-01-06End: 2026-11-24Updated: 2026-02-10
GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Netrin-1 (NP137) in combination with carboplatin plus paclitaxel and/or pembrolizumab in patients with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy
Active, not recruitingCTIS2024-510714-32-00
Start: 2020-12-10Target: 240Updated: 2025-08-19